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Abstract: Deregulation of cyclin-dependent kinases (CDKs) has been associated with many cancer types and has evoked an interest in 
chemical inhibitors with possible therapeutic benefit. While most known inhibitors display broad selectivity towards multiple CDKs, 
recent work highlights CDK9 as the critical target responsible for the anticancer activity of clinically evaluated drugs. In this review, we 
discuss recent findings provided by structural biologists that may allow further development of highly specific inhibitors of CDK9 
towards applications in cancer therapy. We also highlight the role of CDK9 in inflammatory processes and diseases.  
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INTRODUCTION 
  The cyclin-dependent kinase 9 (CDK9) is a serine/threonine 
kinase that forms the catalytic core of the positive transcription 
elongation factor b (P-TEFb) [1-4]. This enzyme is critical for 
stimulating transcription elongation of most protein coding genes, 
including key developmental and stimulus-responsive genes, by 
RNA polymerase II (RNAPII) [5]. RNAPII is paused soon after 
transcription initiation by DSIF and NELF [6]. CDK9 is then 
recruited to the paused transcription complex where it phosphory-
lates DSIF and NELF as well as the RNAPII C-terminal domain, 
and thereby releases RNAPII from the pause site. Activity of CDK9 
is dependent on binding to a regulatory cyclin subunit (cyclin T1, 
T2a or T2b) and is further regulated through association with other 
macromolecules. These modulators include activators like c-myc 
[7], NF-B [8], androgen receptor (AR) [9], Brd4 [10;11], or 
subunits of the super elongation complex [12-14] and inhibitory 
proteins or complexes such as the inhibitory 7SK small nuclear 
RNA (7SK snRNA) containing complex [15-17]. 
  CDK9 belongs to a family of 13 protein kinases that share se-
quence homology and dependence upon the binding of a cyclin 
subunit for activation. Other members of this family are also tran-
scriptional regulators. CDK7/cyclin H is a component of the gen-
eral transcription factor TFIIH and is involved in transcription ini-
tiation [18], CDK7 is also known as the CDK-activating kinase 
(CAK), which activates other CDKs by phosphorylation of the 
activation segment. CDK8/cyclin C and CDK11/cyclin L are in-
volved in mRNA splicing [1]. CDKs 12 and 13 (both activated by 
cyclin K) regulate, like CDK9, transcription elongation by phos-
phorylating the RNAPII CTD [19,20]. Facilitated by their localiza-
tion close to chromatin, CDKs 12 and 13 play additional roles in 
maintenance of genome integrity [2,20].  
  Besides transcription, CDKs regulate other cellular processes 
and were originally identified as the core of the cell cycle control 
system [3,21]. For example, CDKs 4 and 6, complexed with cyclin 
D, link mitogenic signalling to initiation of G1 phase-specific 
transcription by phosphorylating the Rb protein, while CDK2/ 
cyclin A governs DNA replication during S  phase, and CDK1/ 
cyclin B is the master regulator of mitosis, orchestrating and   
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effecting chromosome condensation and nuclear envelope break-
down. The activity of CDKs during the cell cycle is primarily 
regulated by the balance between expression and degradation of 
cyclins, which are usually present in the cell in a phase-specific 
manner. Furthermore, enzymatic activity of CDKs is modulated by 
their phosphorylations (both positive and negative), intracellular 
localization and by the presence of endogenous protein inhibitors 
[3;21], apparent especially at the checkpoints, where progression 
may be blocked until stage-specific processes have completed 
satisfactorily. 
  The complicated system controling progression through the cell 
cycle allows cells to coordinate duplication of chromosomes and 
their equal distribution between both daughter cells with enormous 
precision. Any disturbances to the system may eventually lead to 
qualitative and quantitative changes of DNA content in the nucleus, 
which is often a reason for serious diseases including cancers. 
Accordingly, CDKs and especially their modulators and substrates 
have frequently been found to be deregulated in cancer cells. These 
aberrations in CDK activities led therefore to an intensive search 
for CDK inhibitors for therapeutic applications [22,23]. 
 Flavopiridol  and  roscovitine are the most intensively studied 
CDK inhibitors tested in anticancer clinical trials. Both compounds 
are pan-selective CDK inhibitors; roscovitine inhibits equipotently 
CDK2, 5, 7 and 9, flavopiridol has a preference for inhibition of 
CDK9 over other CDKs (Ki <3 nmol/L compared with Ki values of 
40 to 70 nmol/L for cell-cycle CDKs [24]). While both inhibitors 
influence cell cycle regulation through inhibition of CDKs 1, 2 and 
4, recent work suggests that targeting CDK9 might be critical for 
their anticancer activity [25-29]. In addition, it has been suggested 
that deregulation of CDK9 activity and CDK9-interacting proteins 
are associated with several other human diseases, including ac-
quired immunodeficiency syndrome (AIDS) or cardiac hypertrophy 
[4,30]. Therefore CDK9 emerges as a possible therapeutic target 
[31]. Detailed biochemical characterization of CDK9, as well as the 
availability of crystal structures of its complexes with cyclin T, HIV 
TAT protein, physiological substrate ATP and several small mole-
cule inhibitors (Fig. 1) can now form the basis for rational drug 
development.  
CDK9 STRUCTURE AND IMPLICATIONS FOR STRUC-
TURE-BASED INHIBITOR DESIGN  
  CDK9 has a typical protein kinase fold consisting of an N- and 
a C- terminal kinase lobe and a short C-terminal extension (Fig. 
2A). The ATP-binding site is located between the N- and   
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Fig. (1). CDK inhibitors for which cocrystal structures with CDK9/cyclinT 
are available. 
 
C-terminal lobes and contains highly conserved active site residues 
that coordinate ATP binding and phosphotransfer. Like other 
CDKs, CDK9 is activated by the association with a cyclin, cyclin T, 
and phosphorylation of a threonine residue in the activation seg-
ment, T186. By analogy to CDK2, phosphorylation leads to the 
formation of a stable structure that recognizes the proline residues 
at the +1 position of CDK9 substrates and orients them for phos-
phorylation [32,33]. In contrast to the large interaction interface of 
CDK2/cyclin A, the CDK9/cyclin T interaction is limited. The N-
terminal domain of cyclinT interacts only with the N-terminal 
kinase lobe to support the C-helix in its active conformation (Fig. 
2A). The smaller interaction interface leads to fewer restraints on 
the orientation of the CDK9 N- and C-terminal kinase domains. It 
has been suggested that regulatory factors may bridge between the 
C-terminal kinase and cyclin domains to regulate kinase activity 
and HIV-TAT has subsequently been shown to exploit this binding 
mode [33,34].  
  High sequence conservation among kinases and especially 
members of the CDK family, make it challenging to generate selec-
tive CDK9 inhibitors [30;31]. However, the structural comparison 
of catalytic kinase domains gives insights into small differences of 
the architecture of the ATP binding site and is a powerful tool to 
use in developing inhibitors that are specific for a certain kinase 
[35]. Co-crystal structures of known CDK9 inhibitors like fla-
vopiridol, CR8 and 5,6-dichlorobenzimidazone-1--D-ribofurano-
side (DRB) with CDK9 and CDK2 allowed the comparison of the 
inhibitor binding modes to the two kinases [33;36;37]. While fla-
vopiridol and CR8 bind in the same way in the ATP site of both 
enzymes, DRB adopts a kinase specific orientation. The two chlo-
rine atoms of DRB form halogen bonds to the CDK9 hinge region 
and exploit small geometrical differences to orient the inhibitor 
[37], suggesting that chlorine-halogen bond formation might be 
used to target inhibitors to the CDK9 hinge region with some speci-
ficity (Fig. 2B). 
  Kinases can adopt a range of different conformational states 
that are often characteristic for a specific enzyme and can offer 
further possibilities for targeted inhibitor design. Two different cry- 
stal systems for the active CDK9/cyclin T and CDK9/cyclin T/TAT 
complexes have been reported [33,34]. The two systems trap differ-
ent conformational states of the catalytic kinase subunit, reveal 
variability in the relative dispositions of the N- and C-terminal 
kinase lobes, and identify the glycine-rich loop, the 3-C loop and 
the C helix as flexible elements. 
  It appears that inhibitors showing specificity for CDK9 over 
other CDKs exploit this conformational flexibility. Co-crystal struc-
tures of CDK9/cyclin T with flavopiridol and DRB show a down-
ward movement of the glycine-rich loop to optimally accommodate 
the respective inhibitors [33,37]. This conformation is further stabi-
lized by a concomitant relocation of the 3-C loop, which now 
overlaps with the original position of the glycine-rich loop (Fig. 2B, 
C). Deschloroflavopiridol and DRB binding do not lead to the same 
conformational changes in CDK2/cyclin A, indicating that this 
particular arrangement is CDK9 specific [37,38]. In contrast the 
pan-CDK inhibitor CR8 induces a downward movement of the 
glycine-rich loop in both CDK9 and CDK2 [36]. However, the 
CDK2 ATP-binding site differs from that of CDK9 in that the con-
formational flexibility of the CDK2 3-C loop is independent of 
the position of the glycine-rich loop [39].  
  By compositing the family of inhibitor-bound CDK9 structures 
that adopt a glycine-rich loop down conformation, it is possible to 
define the space in the ATP-binding site that can be exploited in the 
design and further optimization of high affinity CDK9 inhibitors 
(Fig. 2B). An additional factor that may influence the shape of the 
CDK9 ATP-binding site is its little-conserved C-terminal sequence, 
which has to be taken into account when testing inhibitors for their 
affinity and specificity. This extension of the kinase domain was 
shown to increase inhibition of CDK9 by DRB and stabilize the 
protein inhibitor complex [37]. It also changes the binding mode of 
EXEL-8647 to CDK9 [30]. Enzymatic assays and differential fluo-
rescence scanning experiments [40] have been used to assess the C-
terminal dependence of inhibitor binding.  
THE ROLE OF CDK9 IN THE ANTICANCER ACTIVITY 
OF CDK INHIBITORS 
  To date, over 20 potent CDK inhibitors undergo phase I-II 
clinical trials in patients with different cancers [22,23,41]. The 
consequence of administering CDK inhibitors was originally 
expected to be restoration of normal cell cycle in transformed cells 
that proliferate rapidly and with compromised check points. Indeed 
all CDK inhibitors that target cell cycle kinases, such as for 
example flavopiridol, roscovitine or AT7519, display cytostatic 
activity mediated by inhibition of CDK1, 2 and 4 [42;43]. However, 
the antitumour activities of these inhibitors are both highly complex 
and pleiotropic. It took some time to understand why application of 
CDK inhibitors, once believed to target only cell cycle CDKs, leads 
to the induction of cell death. Clear explanation was published by 
Shapiro et al., who demonstrated that depletion of CDKs 1 and 2 
has cytostatic effects, while simultaneous inactivation of CDKs 1, 2 
and 9 induces apoptosis in cancer cell lines [25].  
  Today it is widely accepted that the diverse effects of CDK 
inhibitors is partly due to their ability to block multiple CDKs 
involved in both cell cycle and transcription regulation. The role of 
CDK9 in regulating transcription has been identified as the target of 
most CDK inhibitors that have entered clinical trials. CDK9 
inhibition leads to the downregulation of transcriptionally inducible 
genes with short half-lives, including cell cycle regulators and 
antiapoptotic factors [44]. Although the drugs target several CDKs, 
it has been proposed that the induction of apoptosis arises primarily 
due to the inhibition of CDK9 [26-29;44]. Inhibition of transcrip-
tion (brought about by inhibiting CDK9) leads to a rapid decrease 
not only of D-type cyclins, that support uncontrolled proliferation, 
but also of antiapoptotic proteins XIAP and Mcl-1. Similarly, the 
induction of chronic lymphocytic leukemia cell death induced by 
flavopiridol, SNS-032 or roscovitine is also mediated by the repres-
sion of transcription due to CDK9 inhibition and concomitant 
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down-regulation of XIAP and Mcl-1 [45-47]. A dependence on the 
expression of antiapoptotic proteins is not exclusive to multiple 
myeloma or chronic lymphocytic leukemia. Experimental com-
pound CR8, a congener of roscovitine, potently induces apoptosis 
in neuroblastoma cells, accompanied by Mcl-1 down-regulation 
both at the mRNA and protein levels [48]. Similarly, compound 
VER-54505 reduced levels of Mcl-1 and XIAP in human 
osteosarcoma cell line U2OS [49]. 
  Apart from its antiproliferative and cytotoxic activites caused 
by inhibition of cell-cycle and transcriptional CDKs, flavopiridol 
significantly potentiates the effects of topoisomerase I poisons by 
suppressing Rad51 expression [50]. Rad51 is a protein involved in 
homologous recombination and DNA repair and its down-
regulation after flavopiridol treatment results in enhancement of 
apoptosis. This could be the rationale for the observed clinical ac-
tivity of flavopiridol in combination with DNA damaging drugs 
[51]. 
  CDK9 is often aberrantly activated by oncogenic fusion pro-
teins triggering distinctive lymphoid and myeloid leukemias. In 
particular, the histone methyltransferase MLL forms various fu-
sions with regulators of chromatin modification and transcriptional 
elongation, including proteins of the CDK9 containing SEC 
[12,13,52]. In this light, it is interesting to note that at least two 
CDK inhibitors, including the newly described macrocyclic com-
pound TG02, blocked proliferation and induced apoptosis of acute 
myeloid leukemia cells with MLL rearrangements both in vitro and 
in vivo [53,54]. 
  As a part of the positive transcriptional regulatory complex, 
CDK9 interacts also with the androgen receptor (AR) to enhance 
transcription activity [9]. CDK9 regulates the androgen receptor 
through S81 phosphorylation and this is an important step in regu-
lating not only its transcriptional activity, but also for prostate can-
cer cell growth [55]. It has been shown that pharmacological inhibi-
tion of CDK9 by flavopiridol resulted in decreased AR transcription 
and proliferation rates, which are further potentiated by AR antago-
nist [55].  
  Unexpectedly, some CDK inhibitors (including flavopiridol, 
SNS-032 and roscovitine) have also been shown to inhibit 
angiogenesis  in vitro [56-60]. Although these inhibitors 
demonstrate different kinase-selectivity profiles, so that their 
respective mechanisms of inhibiting angiogenesis may differ, they 
all share significant activity against CDK9. The mechanism 
responsible for the anti-angiogenic properties of both flavopiridol 
and SNS-032 have therefore been partially ascribed to down-
regulation of both mRNA and protein levels of VEGF, the most 
potent tumour angiogenic factor [56;57]. A connection between 
angiogenesis, mRNA transcription and CDK9 has been further 
suggested by analyses of the effects of 4-amino-6-hydrazino-7--D-
ribofura-nosyl-7H-pyrrolo[2,3-d]-pyrimidine-5-carboxamide 
(ARC) and 4-(4-hydroxyphenyl)azo-3,5-diamino-1H-pyrazole 
(CAN508). Both these compounds were originally identified as 
inhibitors of transcription, but they also have anti-angiogenic 
activity in vitro [58,59,61,62]. Anti-angiogenic potential of CDK9 
inhibitors has been highlighted by the finding that a mutation of 
HEXIM1, a negative regulator of CDK9 activity, leads to increased 
VEGF and HIF-1 expression in murine mammary glands [63]. 
However, we recently found that CDK5 also plays an important 
role in angiogenesis. The anti-angiogenic activity of several CDK 
inhibitors with different structures, including roscovitine, arises at 
least partially from interference with CDK5 [60,64]. 
THE INVOLVEMENT OF CDK9 IN INFLAMMATORY 
PROCESSES 
The Role of CDK9 in Inflammatory In vivo Models 
  The precise role of CDK9 in inflammatory processes in vivo 
would best be assessed in CDK9-deficient mice. Unfortunately, 
there are no reports available about attempts to generate these mice 
due to low chances to obtain viable animals: Kohoutek et al. [65] 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Structure and inhibitor binding of CDK9. A: Ribbon model of CDK9/cyclin T (pdb id: 3BLQ) in green and grey, respectively. ATP is represented as 
a yellow stick model and the different elements of the kinase fold are indicated. B: Superposition of CDK9/cyclin T ATP (grey, pdb id: 3BLQ [33]) and DRB 
(lime green, pdb id: 3MY1 [37]) bound structures. Both structures where superposed on their C-terminal kinase domains. CDK9 is represented as ribbon, ATP 
and DRB as stick models, respectively. C: Structures of CDK9 bound SCR8 (pdb id: 3LQ5 [36]) and flavopiridol (pdb id: 3BLR). Same view as in B.  2886    Current Pharmaceutical Design, 2012, Vol. 18, No. 20  Krytof et al. 
showed that cyclin T2, which together with CDK9 forms P-TEFb, 
is essential in mouse embryogenesis. The deletion of cyclin T2 did 
not even allow the appearance of cyclin T2
-/- embryos, not to 
mention pups or adult mice. In C. elegans, the knock-down of 
CDK9 led to embryonic lethality [66] and CDK9-silenced fruit flies 
died during metamorphosis [67]. Consequently, because there are 
no genetically altered mice at hand, the current research depends on 
the usage of kinase inhibitors. Flavopiridol was reported to inhibit 
inflammatory processes in two different mouse models: 
(i)  Flavopiridol is able to dose-dependently suppress murine 
collagen-induced arthritis, even when applied therapeutically, 
that is after the clear clinical manifestation of joint swelling 
[68]. Hallmarks of arthritis, such as cartilage and bone damage 
or leukocyte-infiltrated pannus tissue, were nicely diminished 
in flavopiridol-treated mice. In this setting, flavopiridol did not 
interfere with lymphocyte functions, whereas it strongly 
reduced the proliferation of synovial fibroblasts. This growth 
inhibition did not lead to an induction of apoptosis. Interes-
tingly, even in lymphocyte-deficient mice flavopiridol was 
able to mitigate arthritis, confirming that the compound indeed 
blocks arthritis without affecting lymphocyte function. 
Regarding the molecular target(s) of flavopiridol, the authors 
suggested that the inhibition of CDK4 and 6 plays a crucial 
role in their model, since a CDK4/6-selective inhibitor showed 
comparable pharmacological actions. Perhaps surprisingly, the 
authors did not describe CDK9 as another potential target of 
flavopiridol in arthritis. 
(ii)  We have recently proved that flavopiridol effectively limits 
murine hepatitis induced by concanavalin A (ConA), which 
triggers a strong and rapid leukocyte-dependent inflammatory 
liver injury [69]. The compound inhibited the ConA-evoked 
rise in serum transaminases and protected against neutrophil 
infiltration of the liver tissue. Interestingly, as observed also in 
the above described arthritis model, leukocyte function was 
not altered. However, flavopiridol strongly decreased the 
interaction of neutrophils with endothelial cells (ECs) by 
blocking adhesion molecule expression in ECs. Most impor-
tantly, we could identify CDK9 as the primary target of 
flavopiridol responsible for its profound anti-inflammatory 
effects in vitro. In accordance with this finding, we could also 
demonstrate that the anti-inflammatory action of roscovitine 
derives partly from its inhibition of both CDK5 and CDK9 
[70]. 
CDK9 and Leukocytes 
  In 1998, three publications suggested an association of CDK9 
with the differentiation and function of normal healthy (non-
tumoral) lymphocytes: (i) Arguello et al. [71] reported that 
flavopiridol diminishes the number of lymphocytes in different 
immune organs of normal healthy mice, such as the spleen or 
thymus, by inducing apoptosis. The mitogen-induced proliferation 
of isolated human lymphocytes was also shown to be decreased. (ii) 
Herrmann et al. [72] then showed that CDK9 mRNA and protein 
levels strongly increase upon PHA- or PMA-triggered activation of 
quiescent human peripheral blood lymphocytes (PBLs) and CD4+ 
T cells. (iii) Finally, this was confirmed by Garriga et al. [73], who 
also showed that the expression of CDK9 is upregulated upon 
stimulation of human PBLs by PHA, PMA, or TNF. In parallel, 
cyclin T1 expression is also augmented. Consequently, the 
increased protein concentrations lead to an increase in kinase 
activity of the CDK9/cyclin T1 complex. Later studies confirmed 
and expanded these basic findings [74-76]. CDK9 protein levels 
were found to change during differentiation and activation of B 
lymphocytes: In memory and in activated human B cells the 
expression of CDK9 is increased in comparison to naïve and 
quiescent cells, respectively [77]. Taken together, flavopiridol can 
induce lymphocyte apoptosis, and CDK9 is associated with the 
proliferation and differentiation of lymphocytes. Thus, one could 
hypothesize that inhibition of CDK9 might precipitate immuno-
suppressive actions, thereby leading to beneficial effects parti-
cularly in lymphocyte-driven inflammatory disorders. However, as 
mentioned above, lymphocyte function was not affected in 
flavopiridol-treated arthritis mice, which might argue against this 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Structures of some clinically evaluated CDK inhibitors discussed in the review. 
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hypothesis. Further in vivo pharmacological investigations are 
needed to clarify the potential of CDK9 inhibition in this regard. 
  In contrast to lymphocytes, CDK9 levels are not altered during 
the macrophage differentiation processes [78]. However, a very 
interesting role of CDK9 has been described in primary human 
macrophages [79], the anti-inflammatory cytokine IL-10 inhibits 
transcription of the TNF gene, coding for TNF, by influencing 
transcription elongation in a gene-specific manner: IL-10 blocks the 
p65-mediated recruitment of CDK9 to the TNF gene, but not to the 
NFBIA (coding for IB) promoter. Thus, the “modulation of 
transcription elongation by CDK9” has been highlighted as a 
“unique negative regulatory checkpoint within the human innate 
immune system” [79]. Regarding a putative role for CDK9 in the 
activation of macrophages, Haque et al. [80] recently demonstrated 
that flavopiridol reduces the production of TNF and NO as well as 
the activation of NF-B, IKK, p38 MAPK, JNK, and ERK in LPS-
activated RAW cells (mouse leukemic/monocyte macrophage cell 
line). This suggests an anti-inflammatory potential of flavopiridol in 
the context of LPS-associated immune responses. Although not in 
leukocytes, an influence of flavopiridol on the activation of these 
dominant pro-inflammatory signal transducers has been confirmed 
by Takada et al. [81], who demonstrated that flavopiridol inhibits 
the activation of JNK/AP-1, p38 MAPK, JNK, and ERK, as well as 
the expression of ICAM-1 upon TNF treatment in different cancer 
cell lines. Surprisingly, in the latter two publications, the authors 
did not discuss any role of CDK9 in the processes they investigated. 
However, the results indicate that, not only NF-B, but also the 
MAPK cascade can in principle be influenced by flavopiridol, 
which might contribute to the overall anti-inflammatory action of 
this substance in vitro and in vivo. 
CDK9 and the Pro-inflammatory Transcription Factors NF-B 
and STAT3 
  The transcription factor NF-B plays a prominent role in 
inflammation, since it is involved in the expression of a wide 
variety of inflammatory gene products, such as cytokines or 
adhesion molecules. Indeed, NF-B (p65) binds to and requires P-
TEFb for transcription elongation [8]. By using DRB and a kinase-
deficient CDK9 mutant, P-TEFb/CDK9 kinase activity was shown 
to be necessary for transcription by NF-B. Interestingly, CDK9 
(and cyclin T1) were immunoprecipitated from the TNF-activated 
promoter of IL-8, whose transcription is strongly NF-B-dependent. 
In 2008, Nowak et al. published a study [82], in which they provide 
evidence that the Ser276 phosphorylation of p65 is important for 
the activation of specific NF-B-dependent genes, such as IL-8 and 
GRO, but not IB, and that the association of p65 with 
CDK9/cyclin T1 is critical in this process. Consequently, both 
flavopiridol and the knockdown of CDK9 by siRNA were revealed 
to inhibit the expression of IL-8 and GRO, but not of IB. This 
study implies that the pharmacological inhibition of CDK9 might 
be a valuable anti-inflammatory strategy. In fact, we could show 
that the inhibition of NF-B via blocking CDK9 leads to strong 
anti-inflammatory effects in human endothelial cells [69]: both 
flavopiridol and gene silencing of CDK9 led to a greatly decreased 
ICAM-1 expression, which is responsible for leukocyte recruitment 
into inflammed tissues. We found that flavopiridol did not interfere 
with the TNF-triggered activation cascade of NF-B, comprising 
events such as IKK activation, phosphorylation of IB or p65, 
nuclear transloction of p65, and NF-B binding to DNA. In 
contrast, Takada and Aggarwal reported that each of these events is 
nicely blocked by flavopiridol in different leukemia cell lines [83]. 
This discrepancy has not been investigated in detail yet, but a 
simple explanation would be that flavopiridol exhibits strong cell 
type-dependent actions. Takada and Aggarwal also showed that 
flavopiridol can block the expression of COX-2 and MMP-9, two 
typical pro-inflammatory enzymes. The involvement of CDK9 in 
NF-B-dependent gene transcription was also analyzed by Huang et 
al. [84]: They found that Brd4, a bromodomain-containing protein, 
binds to acetylated p65 and thereby coactivates NF-B in 
cooperation with p300. Brd4, in turn, binds to P-TEFb and activates 
CDK9. By using DRB as well as CDK9 siRNA, the activity and 
presence of CDK9 was shown to be required for Brd4 to coactivate 
TNF-evoked NF-B activity. Taken together, there is good 
evidence that CDK9 is an important regulator of specific NF-B-
driven pro-inflammatory genes and that the anti-inflammatory 
properties of flavopiridol are, at least in part, a result of a blockade 
of the CDK9-activated NF-B pathway. 
  STAT3 represents another very important pro-inflammatory 
transcription factor; CDK9 binds to STAT3 during the IL-6-
induced upregulation of the gene p21
waf1. Accordingly DRB is able 
to suppress the transcription of the p21 gene [85]. The association 
of CDK9 and STAT3 was also confirmed by Hou et al. [86], who 
demonstrated that IL-6 induces the formation of a nuclear 
STAT3/CDK9 complex during hepatic acute phase response. This 
interaction is mediated via the STAT3 NH2-terminal domain. By 
using either flavopiridol or a kinase deficient CDK9 mutant or a 
CDK9 gene silencing approach, the crucial role of CDK9 for the 
IL-6-triggered upregulation of -fibrinogen (a typical acute phase 
gene product) was clearly proven. 
  Taken together, these data indicate that the inhibition of CDK9 
represents an interesting strategy to impede the activation of the 
two prominent pro-inflammatory transcription factors NF-B and 
STAT3. The inhibition of NF-B has been shown to be an 
important mechanism by which flavopiridol exerts its ant-
inflammatory actions [69;70]. Data about STAT3 are lacking in this 
regard. 
CDK9 Binds to TRAF2 and gp130 
 In  1998,  MacLachlan  et al. [87] performed a yeast two-hybrid 
screening of a mouse embryonic library to identify novel CDK9-
binding proteins in the context of mouse developmental processes. 
Interestingly, they disclosed TRAF2, an important protein of the 
TNF receptor complex, to bind to CDK9 in the C-terminal region of 
the TRAF2 protein. Moreover, they showed that CDK9 is present 
both in the nucleus and in the cytosol. By transfection of a kinase-
deficient CDK9 mutant-encoding plasmid, they tested whether 
CDK9 kinase activity is important for the TRAF2-mediated 
activation of NF-B induced by TNF. However, the results from 
these experiments were inconsistent: Both the expression of the 
CDK9 mutant and of wild-type CDK9 exhibited a decreased NF-B 
activity. The authors hypothesized that the overexpression of the 
wild-type CDK9 causes an increased nuclear localization, which 
does not allow to detect cytosolic effects. In 2002, De Falco et al. 
[88] confirmed that CDK9 can also be present in the cytoplasm. 
Furthermore, they described that CDK9 associates with gp130 upon 
IL-6 stimulation. The transmembrane glycoprotein gp130 is an 
important signal transducer and subunit of each of the receptors that 
bind members of the IL-6 cytokine family. It is noteworthy that, 
despite this knowledge about the binding of CDK9 to TRAF2 and 
gp130, it remains unclear whether anti-inflammatory effects of 
CDK9 inhibitors are linked to these two pro-inflammatory signal 
transducers. 
CONCLUSION 
  Targeting CDK9 with small molecule inhibitors represents a 
viable strategy for the treatment of several diseases, indicated espe-
cially by the deregulation of CDK9 activity in cancers, cardiac 
hypertrophy, HIV infections and pathological inflammation. 
However, gaps in our knowledge of CDK9 and its inhibition to date 
have meant that a therapeutic application remains a long way off: 
(i) Unfortunately, many CDK9 inhibitors are unselective, targeting 
several CDKs and other kinases, thus causing significant off-target 
associated toxicity. Inhibitors with a better selectivity for CDK9 
need to be developed. The available CDK9 X-ray structres can 
guide the design of such inhibitors. (ii) CDK9 inhibition (solely by 2888    Current Pharmaceutical Design, 2012, Vol. 18, No. 20  Krytof et al. 
flavopiridol) has as yet only been tested in two inflammatory in 
vivo models (arthritis, hepatitis). Other pathologically relevant 
disease models have to be investigated. (iii) It is of the utmost 
importance to confirm that CDK9 is indeed the critical target for the 
induction of anti-inflammatory effects by CDK9 inhibitors in vivo. 
(iv) The role of CDK9 in the respective disease-relevant cell types 
has to be revealed on a cellular-functional and molecular-
mechanistic basis in much more detail in order to precisely 
understand its mode of action.  
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